SOTIO is a biotechnology company that is developing new Active Cellular Immunotherapy (ACI).
The company focuses on the treatment of cancer and immune system mediated diseases. SOTIO conducts research on its own platform of ACI, based on dendritic cells, as well as its clinical testing in order to launch new medicine into the market. The company develops new medicine, marked as DCVAC/PCa, for prostate cancer patients. In 2012, SOTIO launched “Phase II” clinical trials, involving hundreds of patients. A further goal is to verify the drug’s safety and efficacy in a “Phase III VIABLE” global clinical trial, which commenced in 2014 and includes 1,170 patients.
In 2013, the company started clinical trials of ACI for the treatment of ovarian cancer (the DCVAC/OvCa drug) which take place in the Czech Republic, Germany and Poland. Research focused on ACI for lung cancer treatment (DCVAC/LuCa) is still in its early stage. The company is also looking for other opportunities to further expand its product portfolio.
In 2011, SOTIO built its own cell therapy manufacturing and research facility in Prague - among the most modern in Europe. These super-clean laboratories meet the most stringent requirements for the sterile production of the drugs used in cellular therapy. Similar laboratories were open in 2014 in Beijing.
SOTIO is headquartered in Prague, the Czech Republic, and also has an active presence in the U.S., Russia and China, employing over 370 professionals (as at December 31, 2015).
SOTIO has been part of PPF Group since the end of 2012.
SOTIO N.V.: Management as at June 1, 2015
|Board of Directors||Mr. Marcel Marinus van Santen, Director|
|Jan Cornelis Jansen, Director|
170 00 Prague 7
The Czech Republic
Phone: +420 224 175 111
1077 XX Amsterdam